{"id":"placebo-po-qd","safety":{"commonSideEffects":[{"rate":null,"effect":"Placebo effect (perceived symptom improvement without active drug)"},{"rate":null,"effect":"Nocebo effect (perceived adverse events without active drug)"}]},"_chembl":{"chemblId":"CHEMBL3400969","moleculeType":"Small molecule","molecularWeight":"413.48"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo is an inert substance used as a control in clinical trials. Any observed therapeutic benefit derives from patient expectation, the clinical encounter, and natural disease progression rather than direct molecular action. Placebo is essential for establishing the true efficacy of investigational drugs by comparison.","oneSentence":"Placebo has no active pharmacological mechanism and produces therapeutic effects solely through the placebo effect.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:28:20.556Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Clinical trial control arm (specific indication depends on the trial protocol)"}]},"trialDetails":[{"nctId":"NCT03375320","phase":"PHASE3","title":"Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-10-26","conditions":"Functioning Pancreatic Neuroendocrine Tumor, Intermediate Grade Lung Neuroendocrine Neoplasm, Locally Advanced Digestive System Neuroendocrine Neoplasm","enrollment":298},{"nctId":"NCT05223036","phase":"PHASE2","title":"Testing Obeticholic Acid for Familial Adenomatous Polyposis","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2023-01-19","conditions":"Attenuated Familial Adenomatous Polyposis, Colorectal Carcinoma, Duodenal Carcinoma","enrollment":80},{"nctId":"NCT06954987","phase":"PHASE2","title":"Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-07-17","conditions":"Acute Myeloid Leukemia","enrollment":244},{"nctId":"NCT06009926","phase":"PHASE2","title":"Evaluation of Broccoli Seed and Sprout Extract for Detoxification of Carcinogens in Firefighters","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-12-04","conditions":"Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm, Occupational Malignant Neoplasm","enrollment":72},{"nctId":"NCT05564390","phase":"PHASE2","title":"MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-18","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":2000},{"nctId":"NCT02152982","phase":"PHASE2, PHASE3","title":"Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-12-15","conditions":"Glioblastoma, Gliosarcoma","enrollment":447},{"nctId":"NCT01064648","phase":"PHASE1, PHASE2","title":"Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2010-03-15","conditions":"Epithelioid Mesothelioma, Pleural Malignant Mesothelioma, Recurrent Malignant Mesothelioma","enrollment":117},{"nctId":"NCT04172532","phase":"PHASE1, PHASE2","title":"Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-01-11","conditions":"Locally Advanced Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8","enrollment":92},{"nctId":"NCT05121051","phase":"PHASE2","title":"Testing the Effect of the Broccoli Seed and Sprout Extract, Avmacol ES, on the Cancer Causing Substances of Tobacco in Heavy Smokers","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-09-21","conditions":"Cigarette Smoking-Related Carcinoma","enrollment":135},{"nctId":"NCT05111574","phase":"PHASE2","title":"Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-08-11","conditions":"Anal Melanoma, Bladder Melanoma, Cervical Melanoma","enrollment":101},{"nctId":"NCT01575548","phase":"PHASE3","title":"Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2012-08-08","conditions":"Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v7","enrollment":129},{"nctId":"NCT04939051","phase":"PHASE2","title":"Obeticholic Acid for Prevention in Barrett's Esophagus","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-01-03","conditions":"Barrett Esophagus, Esophageal Adenocarcinoma","enrollment":30},{"nctId":"NCT02968810","phase":"PHASE2","title":"Simvastatin in Preventing Liver Cancer in Patients With Liver Cirrhosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-06-21","conditions":"Cirrhosis, Hepatocellular Carcinoma","enrollment":52},{"nctId":"NCT02193282","phase":"PHASE3","title":"Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-02-11","conditions":"Lung Non-Squamous Non-Small Cell Carcinoma, Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7","enrollment":390},{"nctId":"NCT01841736","phase":"PHASE2","title":"Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2013-09-20","conditions":"Foregut Neuroendocrine Tumor, Hindgut Neuroendocrine Tumor, Metastatic Digestive System Neuroendocrine Tumor G1","enrollment":171},{"nctId":"NCT02194738","phase":"NA","title":"Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-09-26","conditions":"Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Cancer AJCC v8","enrollment":8300},{"nctId":"NCT07303777","phase":"PHASE2","title":"Efficacy, Safety, and PopPK Profile of ABP-745 in Patients With Atherosclerosis","status":"NOT_YET_RECRUITING","sponsor":"Atom Therapeutics Co., Ltd","startDate":"2026-04","conditions":"Atherosclerosis Cardiovascular Disease, ASCVD, ASCVD Management","enrollment":200},{"nctId":"NCT06966778","phase":"NA","title":"Oxybutynin ER to Promote Early Continence Recovery After Robotic Prostatectomy: A Randomized Controlled Trial","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2025-09-15","conditions":"Localized Prostate Cancer, Postoperative Urinary Incontinence","enrollment":135},{"nctId":"NCT06157099","phase":"PHASE2","title":"Atorvastatin for Preventing Disease Metastasis in Patients With Resected High-Risk Stage IIA, IIB, or IIIA Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2024-09-01","conditions":"Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIB Cutaneous Melanoma AJCC v8","enrollment":150},{"nctId":"NCT04527549","phase":"PHASE2","title":"Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma","status":"TERMINATED","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2021-06-01","conditions":"Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8","enrollment":5},{"nctId":"NCT04192136","phase":"NA","title":"NAD+ and Exercise in FA","status":"COMPLETED","sponsor":"Children's Hospital of Philadelphia","startDate":"2020-09-03","conditions":"Friedreich Ataxia 1","enrollment":75},{"nctId":"NCT05535933","phase":"PHASE2, PHASE3","title":"HMPL-523 (Sovleplenib) in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hutchison Medipharma Limited","startDate":"2022-09-30","conditions":"Warm Antibody Autoimmune Hemolytic Anemia","enrollment":110},{"nctId":"NCT06707493","phase":"PHASE2","title":"Ivosidenib as Post-HSCT Maintenance for AML","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2026-01-16","conditions":"IDH1 Mutation, Acute Myeloid Leukemia (AML), Hematopoietic Stem Cell Transplant (HSCT)","enrollment":75},{"nctId":"NCT07456852","phase":"PHASE1, PHASE2","title":"Vasodilator Therapy With Isosorbide Mononitrate or Diltiazem to Reduce Vasotoxicity in Patients With Gastrointestinal Cancer Receiving Fluoropyrimidine Therapy","status":"NOT_YET_RECRUITING","sponsor":"Mayo Clinic","startDate":"2026-03-31","conditions":"Malignant Digestive System Neoplasm","enrollment":60},{"nctId":"NCT07042438","phase":"PHASE2","title":"Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-02-11","conditions":"Recurrent Diffuse Large B-Cell Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma","enrollment":56},{"nctId":"NCT06992427","phase":"PHASE3","title":"High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer","status":"RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2025-06-05","conditions":"Head and Neck Squamous Cell Carcinoma, Stage I Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage II Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8","enrollment":228},{"nctId":"NCT05894239","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-09-08","conditions":"Metastatic Breast Cancer","enrollment":230},{"nctId":"NCT06617455","phase":"PHASE2","title":"Fezolinetant for the Improvement of Vasomotor Symptoms in Breast Cancer Patients Taking Endocrine Therapy, VENT Trial","status":"TERMINATED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2024-10-31","conditions":"Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8","enrollment":9},{"nctId":"NCT04224493","phase":"PHASE3","title":"A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.","status":"RECRUITING","sponsor":"Epizyme, Inc.","startDate":"2020-06-11","conditions":"Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma","enrollment":612},{"nctId":"NCT07172867","phase":"PHASE2","title":"A Ph2 Study to Evaluate the Safety, Efficacy and Tolerability of HT-6184 and Semaglutide in Obese Participants With T2DM","status":"WITHDRAWN","sponsor":"Halia Therapeutics, Inc.","startDate":"2026-01-06","conditions":"Diabetes Mellitus, Type 2, Obesity","enrollment":""},{"nctId":"NCT07408024","phase":"PHASE2","title":"Safety and Efficacy of TollB-001 Tablets in Moderate to Severe Rheumatoid Arthritis","status":"RECRUITING","sponsor":"Toll Biotech Co. Ltd. (Beijing)","startDate":"2025-09-10","conditions":"Rheumatoid Arthritis (RA)","enrollment":24},{"nctId":"NCT05521698","phase":"PHASE1","title":"Study to Determine Possible Effects of Apalutamide, Compared to Placebo, on EGFR Expression in Patients With Non-muscle Invasive Bladder Cancer","status":"NOT_YET_RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2026-04","conditions":"Non-Muscle Invasive Bladder Urothelial Carcinoma, Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma","enrollment":80},{"nctId":"NCT05996627","phase":"PHASE2","title":"Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2023-12-06","conditions":"Chronic Graft Versus Host Disease","enrollment":82},{"nctId":"NCT05937854","phase":"PHASE2","title":"Breathe Easier With Tadalafil Therapy for Dyspnea in COPD-PH","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2024-04-01","conditions":"Chronic Obstructive Pulmonary Disease, Pulmonary Hypertension, Dyspnea","enrollment":126},{"nctId":"NCT07399171","phase":"PHASE2","title":"Study to Evaluate the Effect of HT-4253 for the Prevention of Alzheimer's Disease in APOE4 Carriers","status":"NOT_YET_RECRUITING","sponsor":"Halia Therapeutics, Inc.","startDate":"2026-04-03","conditions":"Alzheimers Disease","enrollment":112},{"nctId":"NCT02271919","phase":"PHASE4","title":"Varenicline and Combined NRT for Smoking Cessation","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-05-14","conditions":"Cigarette Smoker, Tobacco Use Disorder","enrollment":631},{"nctId":"NCT04455750","phase":"PHASE3","title":"A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2021-10-14","conditions":"Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8","enrollment":61},{"nctId":"NCT01628029","phase":"PHASE2","title":"Cognitive Behavioral Therapy and Multimodal Therapy in Treating Sleep Disturbance in Patients With Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2014-01-15","conditions":"Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Sleep Disorder","enrollment":68},{"nctId":"NCT07378098","phase":"PHASE3","title":"to Evaluate the Efficacy and Safety of KLH-2109 in Patients With Uterine Fibroids and Menorrhagia","status":"RECRUITING","sponsor":"JW Pharmaceutical","startDate":"2026-01-26","conditions":"Menorrhagia, Uterine Fibroids","enrollment":254},{"nctId":"NCT05123703","phase":"PHASE3","title":"A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis (RRMS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-05-19","conditions":"Relapsing-Remitting Multiple Sclerosis","enrollment":188},{"nctId":"NCT04650581","phase":"PHASE3","title":"Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor","status":"ACTIVE_NOT_RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2021-01-27","conditions":"Breast Cancer","enrollment":250},{"nctId":"NCT04137107","phase":"PHASE2, PHASE3","title":"Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2020-06-17","conditions":"Stage II Colorectal Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8","enrollment":220},{"nctId":"NCT04767984","phase":"PHASE2","title":"Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Northwestern University","startDate":"2021-09-24","conditions":"Colorectal Carcinoma, Ulcerative Colitis","enrollment":42},{"nctId":"NCT05561738","phase":"NA","title":"Nicotinamide Riboside in Ulcerative Colitis","status":"RECRUITING","sponsor":"University of Pittsburgh","startDate":"2024-02-28","conditions":"Ulcerative Colitis","enrollment":40},{"nctId":"NCT03996265","phase":"PHASE3","title":"Bupropion to Reduce Cancer Related Fatigue in Cancer Survivors","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Rochester NCORP Research Base","startDate":"2019-06-27","conditions":"Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm","enrollment":422},{"nctId":"NCT03422822","phase":"PHASE3","title":"Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-03-08","conditions":"Dermatitis, Atopic","enrollment":3166},{"nctId":"NCT03371719","phase":"PHASE2","title":"Radiation Therapy With or Without Apalutamide in Treating Patients With Recurrent Prostate Cancer, the BALANCE Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"NRG Oncology","startDate":"2018-06-20","conditions":"Recurrent Prostate Carcinoma, Stage III Prostate Adenocarcinoma AJCC v7, Stage IV Prostate Adenocarcinoma AJCC v7","enrollment":324},{"nctId":"NCT05053152","phase":"PHASE2","title":"Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2022-04-20","conditions":"Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma, Prostate Ductal Adenocarcinoma","enrollment":194},{"nctId":"NCT06431373","phase":"PHASE3","title":"A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Priovant Therapeutics, Inc.","startDate":"2024-09-11","conditions":"Uveitis, Posterior, Uveitis, Intermediate, Uveitis","enrollment":371},{"nctId":"NCT06026371","phase":"PHASE2","title":"Fecal Microbiota Transplantation for the Prevention of Acute Graft Versus Host Disease in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2023-12-12","conditions":"Acute Graft Versus Host Disease, Hematopoietic and Lymphatic System Neoplasm","enrollment":138},{"nctId":"NCT01196936","phase":"PHASE2","title":"Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2010-09","conditions":"Breast Cancer","enrollment":84},{"nctId":"NCT04939597","phase":"PHASE3","title":"A Study to See if Memantine Protects the Brain During Radiation Therapy Treatment for a Brain Tumor","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2022-05-10","conditions":"Central Nervous System Carcinoma","enrollment":192},{"nctId":"NCT02115282","phase":"PHASE3","title":"Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-03-29","conditions":"Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Breast Adenocarcinoma","enrollment":608},{"nctId":"NCT04120766","phase":"PHASE2","title":"Safety and Modulation of ABCC9 Pathways by Nicorandil for the Treatment of Hippocampal Sclerosis of Aging","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gregory Jicha, MD, PhD","startDate":"2021-12-01","conditions":"Dementia, Mild Cognitive Impairment","enrollment":64},{"nctId":"NCT06731894","phase":"PHASE2","title":"Phytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2025-10-03","conditions":"Breast Carcinoma, Chemotherapy-Induced Peripheral Neuropathy, Colon Carcinoma","enrollment":120},{"nctId":"NCT05194397","phase":"PHASE2","title":"Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors","status":"RECRUITING","sponsor":"Children's Hospital of Philadelphia","startDate":"2023-02-23","conditions":"Lymphoblastic Leukemia, Cancer Survivors, Aplastic Anemia","enrollment":80},{"nctId":"NCT05474846","phase":"PHASE2, PHASE3","title":"Combination Therapy for Treatment of Sleep Disturbance in Patients With Advanced Cancer","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-11-21","conditions":"Sleep, Fatigue, Anxiety","enrollment":188},{"nctId":"NCT04262206","phase":"PHASE4","title":"Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults","status":"RECRUITING","sponsor":"Duke University","startDate":"2020-09-01","conditions":"Cognitive Impairment, Mild, Dementia, Cardiovascular Diseases","enrollment":20000},{"nctId":"NCT02521285","phase":"PHASE2","title":"Aspirin in Preventing Disease Recurrence in Patients With Barrett Esophagus After Successful Elimination by Radiofrequency Ablation","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-01-15","conditions":"Barrett Esophagus, Esophageal Adenocarcinoma","enrollment":21},{"nctId":"NCT03525873","phase":"PHASE3","title":"A Study of Cancer Related Fatigue in Patients With Metastatic Cancer Receiving Anti-PD1 Immunotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-08-02","conditions":"Advanced Malignant Neoplasm, Metastatic Malignant Neoplasm, Recurrent Malignant Neoplasm","enrollment":212},{"nctId":"NCT06143891","phase":"PHASE3","title":"A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2024-01-23","conditions":"Chronic Graft Versus Host Disease","enrollment":260},{"nctId":"NCT07215910","phase":"PHASE3","title":"Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer","status":"NOT_YET_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2025-10-20","conditions":"Astrocytoma, IDH-Mutant, Grade 3","enrollment":408},{"nctId":"NCT03796884","phase":"PHASE2","title":"Linaclotide in Treating Patients With Stages 0-3 Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2019-10-30","conditions":"Colorectal Adenoma, Stage 0 Colorectal Cancer AJCC v8, Stage I Colorectal Cancer AJCC v8","enrollment":230},{"nctId":"NCT03057054","phase":"PHASE3","title":"Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2018-04-30","conditions":"Acute Graft Versus Host Disease, Hematopoietic and Lymphatic System Neoplasm, Leukemia","enrollment":173},{"nctId":"NCT05437263","phase":"PHASE3","title":"A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Dermatomyositis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Priovant Therapeutics, Inc.","startDate":"2022-10-31","conditions":"Dermatomyositis","enrollment":241},{"nctId":"NCT05237960","phase":"PHASE2","title":"Metformin for the Prevention of Oral Cancer in Patients With Oral Leukoplakia or Erythroplakia","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Arizona","startDate":"2023-01-12","conditions":"Erythroplakia, Oral Leukoplakia","enrollment":34},{"nctId":"NCT05246670","phase":"PHASE2","title":"PEA for the Relief of Chemotherapy-Induced Peripheral Neuropathy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Academic and Community Cancer Research United","startDate":"2022-05-16","conditions":"Chemotherapy-Induced Peripheral Neuropathy, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm","enrollment":88},{"nctId":"NCT06979609","phase":"PHASE2, PHASE3","title":"Secondary Prevention of Clostridioides Difficile Using Vancomycin","status":"RECRUITING","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2025-10-01","conditions":"Clostridioides Difficile Infection, Clostridioides Difficile Infection Recurrence, Clostridoides Difficile Associated Disease","enrollment":300},{"nctId":"NCT04851613","phase":"PHASE3","title":"Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer","status":"RECRUITING","sponsor":"Laekna Limited","startDate":"2022-02-18","conditions":"Breast Cancer","enrollment":256},{"nctId":"NCT04478266","phase":"PHASE3","title":"Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer","status":"TERMINATED","sponsor":"Sanofi","startDate":"2020-10-14","conditions":"Breast Cancer","enrollment":1068},{"nctId":"NCT05085561","phase":"PHASE2","title":"The Symptomatic Cerebral Cavernous Malformation Trial of REC-994","status":"COMPLETED","sponsor":"Recursion Pharmaceuticals Inc.","startDate":"2022-03-17","conditions":"Cerebral Cavernous Malformation","enrollment":62},{"nctId":"NCT02908672","phase":"PHASE3","title":"A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-01-13","conditions":"Melanoma","enrollment":514},{"nctId":"NCT03834493","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-07-28","conditions":"Prostatic Neoplasms","enrollment":1244},{"nctId":"NCT03087708","phase":"PHASE2","title":"Naloxegol in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer","status":"TERMINATED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2018-03-23","conditions":"Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer","enrollment":50},{"nctId":"NCT06055179","phase":"NA","title":"XCHT for Irinotecan-Induced Gut Toxicities (Randomized Controlled Trial)","status":"RECRUITING","sponsor":"Guangzhou University of Traditional Chinese Medicine","startDate":"2024-03-08","conditions":"Xiao Chai Hu Tang, Irinotecan-induced Diarrhea","enrollment":98},{"nctId":"NCT03941860","phase":"PHASE3","title":"Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2022-02-16","conditions":"Multiple Myeloma","enrollment":1},{"nctId":"NCT04906421","phase":"PHASE2","title":"Study of TVB-2640 in Subjects With Nonalcoholic Steatohepatitis (NASH)","status":"COMPLETED","sponsor":"Sagimet Biosciences Inc.","startDate":"2021-08-12","conditions":"Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease","enrollment":168},{"nctId":"NCT03109873","phase":"EARLY_PHASE1","title":"Metformin Hydrochloride in Affecting Cytokines and Exosomes in Patients With Head and Neck Cancer","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2017-01-05","conditions":"Larynx, Lip, Oral Cavity","enrollment":9},{"nctId":"NCT06014528","phase":"PHASE2","title":"IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer","status":"RECRUITING","sponsor":"InxMed (Shanghai) Co., Ltd.","startDate":"2022-09-06","conditions":"Ovarian Cancer Recurrent","enrollment":168},{"nctId":"NCT00664313","phase":"PHASE1, PHASE2","title":"TBTC Study 30: Safety and Tolerability of Low Dose Linezolid in MDR TB","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2009-04","conditions":"Multi-drug Resistant Tuberculosis, Extensively Drug Resistant Tuberculosis","enrollment":36},{"nctId":"NCT02717507","phase":"PHASE2","title":"Carvedilol in Preventing Heart Failure in Childhood Cancer Survivors","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2016-04-04","conditions":"Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm","enrollment":196},{"nctId":"NCT05342194","phase":"PHASE3","title":"Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study","status":"RECRUITING","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2023-06-19","conditions":"Intrahepatic Cholangiocarcinoma","enrollment":480},{"nctId":"NCT03267680","phase":"PHASE2","title":"IRX-2 Regimen in Treating Women With Cervical Squamous Intraepithelial Neoplasia 3 or Squamous Vulvar Intraepithelial Neoplasia 3","status":"TERMINATED","sponsor":"University of Southern California","startDate":"2017-11-08","conditions":"Cervical Squamous Cell Carcinoma In Situ, Vulvar High Grade Squamous Intraepithelial Lesion","enrollment":10},{"nctId":"NCT01905046","phase":"PHASE3","title":"Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2015-11-23","conditions":"Atypical Ductal Breast Hyperplasia, BRCA1 Mutation Carrier, BRCA2 Mutation Carrier","enrollment":86},{"nctId":"NCT05904717","phase":"PHASE2","title":"Effect of PXS-4728A on Microglia Activation in Participants With Isolated Rapid Eye Movement Sleep Behaviour Disorder","status":"ACTIVE_NOT_RECRUITING","sponsor":"Syntara","startDate":"2023-11-08","conditions":"REM Sleep Behavior Disorder","enrollment":40},{"nctId":"NCT06052748","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of AD-223","status":"COMPLETED","sponsor":"Addpharma Inc.","startDate":"2024-02-15","conditions":"Hypertension,Essential","enrollment":502},{"nctId":"NCT05618587","phase":"PHASE2","title":"Effect of Lithium Therapy on Long COVID Symptoms","status":"COMPLETED","sponsor":"State University of New York at Buffalo","startDate":"2022-11-28","conditions":"Long COVID","enrollment":52},{"nctId":"NCT06103825","phase":"PHASE3","title":"A Twelve-week, Double-blind, Placebo-controlled, Randomized, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Solriamfetol in the Treatment of Excessive Daytime Sleepiness (EDS) in Patients with Obstructive Sleep Apnea (OSA)","status":"COMPLETED","sponsor":"Ignis Therapeutics (Suzhou) Limited","startDate":"2023-08-01","conditions":"Sleep Apnea, Obstructive, Excessive Daytime Sleepiness","enrollment":204},{"nctId":"NCT02694809","phase":"PHASE2","title":"The PROMISE Study: Duavee in Women With DCIS","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2017-01","conditions":"Ductal Breast Carcinoma In Situ, Postmenopausal","enrollment":142},{"nctId":"NCT03830762","phase":"PHASE1","title":"Xanamem™ in Healthy Elderly Subjects","status":"COMPLETED","sponsor":"Actinogen Medical","startDate":"2019-01-21","conditions":"Safety, Peripheral Neuropathy, Cortisol","enrollment":42},{"nctId":"NCT04691804","phase":"PHASE3","title":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2021-03-18","conditions":"Metastatic Castration-Resistant Prostate Cancer (mCRPC)","enrollment":496},{"nctId":"NCT06647550","phase":"PHASE2","title":"To Assess the Efficacy and Safety of HD-6277 in Adult Patients With Inadequate Control of Type 2 Diabetes Mellitus by Diet and Exercise","status":"RECRUITING","sponsor":"Hyundai Pharm","startDate":"2024-12-12","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":160},{"nctId":"NCT01950403","phase":"PHASE1","title":"Linaclotide Acetate in Preventing Colorectal Cancer in Healthy Volunteers","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2013-09","conditions":"Colorectal Cancer, Healthy, no Evidence of Disease","enrollment":24},{"nctId":"NCT06715319","phase":"PHASE3","title":"Obeticholic Acid Versus Placebo, in Combination with Ursodeoxycholic Acid in Patients with Primary Biliary Cirrhosis","status":"COMPLETED","sponsor":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.","startDate":"2021-10-09","conditions":"PBC","enrollment":100},{"nctId":"NCT01064622","phase":"PHASE2","title":"Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2009-09-03","conditions":"Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage IV Pancreatic Cancer AJCC v6 and v7","enrollment":118},{"nctId":"NCT04060862","phase":"PHASE1","title":"A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2019-11-21","conditions":"Breast Cancer","enrollment":20},{"nctId":"NCT01400412","phase":"PHASE2","title":"Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2012-01-17","conditions":"HIV-1 Infection","enrollment":262},{"nctId":"NCT06504420","phase":"PHASE2","title":"The Safety and Efficiency of Sirolimus in Primary Antiphospholipid Syndrome: a Randomized Control Study","status":"NOT_YET_RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2024-10-15","conditions":"Primary Antiphospholipid Syndrome","enrollment":70},{"nctId":"NCT05450887","phase":"PHASE3","title":"Efficacy and Safety of Obeticholic Acid in the Treatment of Primary Biliary Cholangitis","status":"COMPLETED","sponsor":"Nanjing Chia-tai Tianqing Pharmaceutical","startDate":"2021-09-23","conditions":"Primary Biliary Cholangitis","enrollment":108},{"nctId":"NCT04532372","phase":"PHASE1, PHASE2","title":"Leflunomide for the Treatment of Severe COVID-19 in Patients With a Concurrent Malignancy","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2021-01-07","conditions":"Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Symptomatic COVID-19 Infection Laboratory-Confirmed","enrollment":2}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo PO QD","genericName":"Placebo PO QD","companyName":"Priovant Therapeutics, Inc.","companyId":"priovant-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Placebo PO QD is a placebo intervention used in clinical trials, and it has been studied in various conditions including Ductal Breast Carcinoma In Situ, HER2/Neu Positive, Differentiated Thyroid Cancer, Bipolar Disorder, and Multiple Myeloma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}